{
    "clinical_study": {
        "@rank": "83916", 
        "acronym": "DK PRECISE", 
        "arm_group": [
            {
                "arm_group_label": "Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Yeast tablet", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a pilot study proceeding an intended international trial.\n\n      Hypothesis: Daily intake of selenium supplementation in the form of selenium-enriched yeast\n      tablets will reduce the risk of cancer in healthy individuals.\n\n      Objective: The objective of this pilot study was to assess the viability of a full scale\n      randomised trial."
        }, 
        "brief_title": "Selenium in the Prevention of Cancer", 
        "completion_date": {
            "#text": "June 2004", 
            "@type": "Actual"
        }, 
        "condition": "Cancer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  WHO performance status 0 or 1\n\n          -  No active liver- or kidney disease (Serum ALAT (alanine aminotransferase), alkalic\n             phosphatase, bilirubin, creatinin or urea within 2 S.D of laboratory reference range)\n\n          -  No previous cancer diagnosis\n\n          -  No known HIV-infection\n\n          -  Participant must understand oral and written information\n\n          -  Participant must not use selenium supplementation of above 50 mcg/d\n\n          -  Participant must give written consent prior to inclusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "74 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "491", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819649", 
            "org_study_id": "OUH-DK-PILOT-PRECISE"
        }, 
        "intervention": {
            "arm_group_label": [
                "Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d", 
                "Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d", 
                "Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d"
            ], 
            "intervention_name": "SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": "Selenium"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "selenium", 
            "selenium supplementation", 
            "randomised controlled trial", 
            "prevention"
        ], 
        "lastchanged_date": "March 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Odense C", 
                    "country": "Denmark", 
                    "zip": "5000"
                }, 
                "name": "Selenium Centre, Odense University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "4", 
        "official_title": "Prevention of Cancer by Intervention With Selenium - A Pilot Study in a Danish Population", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "At five years intervention (last participant last visit was june 2004) viability of full scale study was assessed according to the drop out rate, cost etc. of this pilot study.", 
            "measure": "Viability of full scale study", 
            "safety_issue": "No", 
            "time_frame": "At five years intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819649"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Odense University Hospital", 
            "investigator_full_name": "S\u00f8ren Cold", 
            "investigator_title": "M.D. PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Odense University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Danish Cancer Society", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Southern Denmark", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The K.A. Rohde and Wife Foundation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The County of Funen, Denmark", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Cypress Systems, USA", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Dagmar Marshall Foundation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The N. O. Andersen Foundation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Danish Directory of Food and Agriculture", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Foundation of Clinical Experimental Cancer Research, Odense", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Foundation of Lily Benthine Lund", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Memory Foundation of Merchant Brogaard", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Pharma Nord", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Odense University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 1998", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}